France · Series B startup

Who invested in Genomic Vision

2 rounds we have observed, with the 3 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Funding summaryUpdated 26 Oct 2026

$8.7Mraised across 2 rounds since 2005, from 2 sources

$2.4MSeries A$6.3MSeries B
Latest round
Series B, $6.3MJul 2008
Step-upi
2.6×
Investors
3
See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

200620072008
$2.4MSeries A$6.3MSeries B
First round
Series A, $2.4M
Dec 2005
Biggest round
$6.3M
Series B · Jul 2008
Between rounds
2.6 years
from the last two

The rounds

  1. Jul 2008
    Series B$6.3M2 new

    From a historical funding record

  2. Dec 2005
    Series A$2.4M1 new

    From a historical funding record

Who was in which round

The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.

Everyone who backed them

Missing a round, or an investor who was in one? Tell us.

Quick answers about Genomic Vision

Who invested in Genomic Vision?

Genomic Vision's investors include SG Asset Management Private Equity, Societe Generale Asset Management and Vesalius Biocapital III.

How much has Genomic Vision raised?

Genomic Vision has raised $8.7M across 2 rounds since 2005.

When did Genomic Vision last raise?

Genomic Vision's most recent round was a Series B of $6.3M in Jul 2008.

What was Genomic Vision's biggest round?

Its most recent round, $6.3M in Jul 2008, is also its largest on record.

Who backed Genomic Vision first?

Genomic Vision's first round on record, in Dec 2005, was backed by SG Asset Management Private Equity.

What stage is Genomic Vision at?

Genomic Vision's latest named round is a Series B, in Jul 2008.

Where is Genomic Vision based?

Genomic Vision is based in France.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.